DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

REKinDLE: Registry With Enbrel® or Kineret® in a Database Using Longitudinal Evaluations

Information source: Amgen
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Rheumatoid Arthritis

Intervention: Enbrel (Drug); Kineret (Drug)

Phase: N/A

Status: Completed

Sponsored by: Amgen

Official(s) and/or principal investigator(s):
MD, Study Director, Affiliation: Amgen


The purpose of this study is to determine if Enbrel or Kineret will have a positive effect on subject functionality as measured by the Health Assessment Questionnaire Disability Index (HAQDI).

Clinical Details

Official title: Registry With Enbrel or Kineret in a Database Using Longitudinal Evaluations (REKinDLE)

Study design: Time Perspective: Prospective


Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria: - Subjects with active rheumatoid arthritis as defined by ACR criteria

- Able to start Enbrel® or Kineret® therapy (per the approved product monographs) within

approximately 30 days of confirmed enrolment Exclusion Criteria: - Active infections at

the time of initiating Enbrel® or Kineret® therapy - Malignancy other than basal cell

carcinoma of the skin or, in situ carcinoma of the cervix, within the past 5 years - Known

hypersensitivity to E. coli derived products - Known hypersensitivity to Enbrel® or any of

its components - Subjects receiving, or who received:* Enbrel® in the previous 30 days; *

Remicade® in the previous 3 months; * Humira® in the previous 3 months; * Kineret® in the

previous 15 days. - Subjects beginning Enbrel® therapy, or treated with prior or current

treatment using Enbrel® - Subjects beginning Kineret® therapy, or treated with prior or

current treatment using Kineret® - Treatment with any investigational therapy in the 30

days prior to enrolment confirmation - Presence of any significant and uncontrolled

medical condition which, in the investigator's opinion, precludes the use of Enbrel® -

Sepsis or at risk of septic syndrome

Locations and Contacts

Additional Information

AmgenTrials clinical trials website

Notice regarding posted summaries of trial results

To access clinical trial results information click on this link

Starting date: September 2002
Last updated: December 4, 2008

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017